Are thiazolidinediones associated with an increased risk of heart failure and cardiovascular death?: Commentary

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 5, 2008, Pages 244-245

  Dandona, Paresh ^a   Chaudhuri, Ajay ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLITAZONE DERIVATIVE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG INDICATION; EDEMA; FLUID RETENTION; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; SIDE EFFECT; WEIGHT GAIN;

EID: 42649131389     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1121     Document Type: Short Survey

References (6)

1. Yki-Järvinen H (2004) Thiazolidinediones. N Engl J Med 351 1106-1118
2. Dargie HJ et al. (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 49: 1696-1704
3. Nissen SE and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471
4. Home PD et al. for the RECORD Study Group (2007) Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 357: 28-38
5. Dormandy JA et al. for the PROactive investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366: 1279-1289
6. Ghanim H et al. (2006) Low dose rosiglitazone exerts an anti-inflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab 91: 3553-3558